Loading...
XNASTCBPW
Market cap205kUSD
Jan 07, Last price  
0.02USD
1D
13.64%
1Q
-25.00%
IPO
-97.17%
Name

TC BioPharm Ltd

Chart & Performance

D1W1MN
XNAS:TCBPW chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
-100.00%
3,426,8461,978,6591,978,6593,844,5320
Net income
-6m
L+349.68%
-6,067,984-5,457,916-13,575,925-1,313,601-5,906,953
CFO
-11m
L-31.04%
-6,729,623-3,431,868-5,581,022-15,292,297-10,544,870

Profile

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
URL
https://tcbiopharm.com/
IPO date
Feb 11, 2022
Employees
60
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑12
Income
Revenues
3,845
94.30%
Cost of revenue
14,642
16,331
Unusual Expense (Income)
NOPBT
(14,642)
(12,486)
NOPBT Margin
Operating Taxes
(1,089)
1,720
Tax Rate
NOPAT
(13,553)
(14,206)
Net income
(5,907)
349.68%
(1,314)
-90.32%
Dividends
Dividend yield
Proceeds from repurchase of equity
4,187
BB yield
-4,275.47%
Debt
Debt current
305
653
Long-term debt
4,793
3,922
Deferred revenue
Other long-term liabilities
(1,496)
Net debt
2,636
(233)
Cash flow
Cash from operating activities
(10,545)
(15,292)
CAPEX
(110)
(241)
Cash from investing activities
(209)
(310)
Cash from financing activities
8,520
18,653
FCF
(13,940)
(15,743)
Balance
Cash
2,463
4,808
Long term investments
Excess cash
2,463
4,616
Stockholders' equity
(38,835)
(32,977)
Invested Capital
43,322
35,759
ROIC
ROCE
EV
Common stock shares outstanding
31
Price
3.17
-17.66%
3.85
 
Market cap
98
 
EV
2,733
EBITDA
(14,009)
(11,527)
EV/EBITDA
Interest
Interest/NOPBT